These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38972151)

  • 21. Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma.
    Alnaggar M; Xu Y; Li J; He J; Chen J; Li M; Wu Q; Lin L; Liang Y; Wang X; Li J; Hu Y; Chen Y; Xu K; Wu Y; Yin Z
    J Immunother Cancer; 2019 Feb; 7(1):36. PubMed ID: 30736852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
    Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
    Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.
    Nelson MA; Ngamcherdtrakul W; Luoh SW; Yantasee W
    Cancer Metastasis Rev; 2021 Jun; 40(2):519-536. PubMed ID: 33963482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic depletion of CCR8
    Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes.
    Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
    Mod Pathol; 2021 Apr; 34(4):798-807. PubMed ID: 33077921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.
    Lee JC; Mehdizadeh S; Smith J; Young A; Mufazalov IA; Mowery CT; Daud A; Bluestone JA
    Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33008914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma.
    Supimon K; Sangsuwannukul T; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
    Sci Rep; 2021 Mar; 11(1):6276. PubMed ID: 33737613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remodeling of the tumor microenvironment via disrupting Blimp1
    Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
    Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of transcriptional and immunological disparities among patient groups with varied prognostic risk factors in cholangiocarcinoma.
    Zhang B; Jin B; Wu X; Xing J; Liu X; Wan X; Xu H; Xu Y; Mao Y; Chen Q; Bai Y; Guan M; Du S
    Cancer Med; 2024 Aug; 13(16):e70135. PubMed ID: 39206584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
    Alvisi G; Termanini A; Soldani C; Portale F; Carriero R; Pilipow K; Costa G; Polidoro M; Franceschini B; Malenica I; Puccio S; Lise V; Galletti G; Zanon V; Colombo FS; De Simone G; Tufano M; Aghemo A; Di Tommaso L; Peano C; Cibella J; Iannacone M; Roychoudhuri R; Manzo T; Donadon M; Torzilli G; Kunderfranco P; Di Mitri D; Lugli E; Lleo A
    J Hepatol; 2022 Nov; 77(5):1359-1372. PubMed ID: 35738508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune contexture of cholangiocarcinoma.
    Paillet J; Kroemer G; Pol JG
    Curr Opin Gastroenterol; 2020 Mar; 36(2):70-76. PubMed ID: 31895228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma.
    Kitano Y; Okabe H; Yamashita YI; Nakagawa S; Saito Y; Umezaki N; Tsukamoto M; Yamao T; Yamamura K; Arima K; Kaida T; Miyata T; Mima K; Imai K; Hashimoto D; Komohara Y; Chikamoto A; Ishiko T; Baba H
    Br J Cancer; 2018 Jan; 118(2):171-180. PubMed ID: 29123259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications.
    Yu F; Gong L; Mo Z; Wang W; Wu M; Yang J; Zhang Q; Li L; Yao J; Dong J
    Biosci Trends; 2019 Mar; 13(1):58-69. PubMed ID: 30773525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
    Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
    Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-associated macrophages: orchestrators of cholangiocarcinoma progression.
    Chen F; Sheng J; Li X; Gao Z; Hu L; Chen M; Fei J; Song Z
    Front Immunol; 2024; 15():1451474. PubMed ID: 39290697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells.
    Panya A; Thepmalee C; Sawasdee N; Sujjitjoon J; Phanthaphol N; Junking M; Wongkham S; Yenchitsomanus PT
    Cancer Immunol Immunother; 2018 Oct; 67(10):1579-1588. PubMed ID: 30056600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion.
    Ye Y; Zhou L; Xie X; Jiang G; Xie H; Zheng S
    J Surg Oncol; 2009 Nov; 100(6):500-4. PubMed ID: 19697355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.